Product Images Beovu

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 16 images provide visual information about the product associated with Beovu NDC 0078-0827 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Preparation for Administration - Store BEOVU in the refrigerator between 2 to 8°C (36 to 46°F); do not freeze. Keep the vial in the outer carton to protect from light. - rth258 01

Preparation for Administration - Prior to use, the unopened glass vial of BEOVU may be kept at room temperature, 20 to 25°C (68 to 77°F) for up to 24 hours. After opening the glass vial, proceed under aseptic conditions. - rth258 02

Preparation for Administration - BEOVU is a clear to slightly opalescent and colorless to slightly brownish-yellow solution. - rth258 03

Preparation for Administration - BEOVU should be inspected visually upon removal from the refrigerator and prior to administration. If particulates, cloudiness, or discoloration are visible, the glass vial must not be used. The BEOVU kit includes the sterile glass vial and filter needle which are for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired [see How Supplied/Storage and Handling (16)]. - rth258 04

Figure 1: - rth258 05

Figure 2: - rth258 06

Figure 3: - rth258 07

Figure 4: - rth258 08

Figure 5: Mean Change in Visual Acuity From Baseline to Week 96 in HAWK - rth258 09

This is a chart that displays BCVA (best corrected visual acuity) changes from baseline in letters over a span of 96 weeks for two drugs - BEOVU and Aflibercept 2mg. The study was called HAWK and involved 360 participants for each drug. The horizontal axis represents time in weeks while the vertical axis depicts the change in BCVA in letters.*

Figure 6: Mean Change in Visual Acuity From Baseline to Week 96 in HARRIER - rth258 10

PRINCIPAL DISPLAY PANEL NDC 0078 0827 61 Beovu (brolucizumab-dbll) Injection 6 mg/0.05 mL Single-dose Vial; Discard unused portion. For Intravitreal Use Carton contains: 1 x 2 mL vial, 1 x filter needle NOVARTIS - rth258 11

Beovu is a medication used for injection in treating certain eye conditions. It is designed to be stored in an unopened, refrigerated vial and discarded if unused. Each vial contains 0.05 mL of a solution containing 6mg/0.05mL of brolucizumab-dbll. Once opened, the un-used glass vial of Beovu can be kept at room temperature for 24 hours. Additional dosage and prescribing information are available on the manufacturer's website or by calling the company directly. The medication is manufactured by Novartis Pharmaceuticals Corporation.*

rth258 12

This looks like a description of a syringe. It has a cap and finger grip for easy handling, and a rubber stopper to prevent leakage. It appears to be calibrated in 0.05mL increments and has a Luer Lock mechanism to securely attach a needle. The plunger rod is also mentioned, likely used to control the amount of fluid drawn or dispensed.*

rth258 13

rth258 14

rth258 15

rth258 16

The text appears to be a chart depicting the change in visual acuity (VA) from baseline in letters, for two different treatments (Beovu and Aflibercept) over a period of 52 weeks. The first column represents the week number, and the subsequent columns represent the VA change in letters at corresponding weeks. There are some missing values denoted by dashes. The sample size (N) for both treatments is also provided.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.